Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer In FDA's Bad Books Over Facility Failures

Executive Summary

Not for the first time this decade, the German major has been warned by the US FDA about its manufacturing processes and sorting out the problems could affect supplies of some big-selling  products such as the blood pressure treatment Adalat and the erectile dysfunction drug Levitra.

You may also be interested in...



China Pharma Sales Bring Bayer Relief From Monsanto Legal Woes

Xarelto and Eylea are continuing to sell well but the German major faces another heap of litigation in the US over Monsanto's weedkillers which is alarming shareholders.

Bayer Eyes More Link-Ups Like Loxo After Pipeline Blips

Litigation woes at Monsanto are casting a shadow over Bayer but despite the news of some discontinued projects, the German major sees pharma as an integral component and will keep investing in its pipeline.

Signs Of Improving FDA Inspection Outcomes At Indian Sites But Long Road Ahead

Moving up the manufacturing compliance curve is still a work in progress for several Indian firms, but there appear to be some early signs that US FDA inspection outcomes, in general, may have improved.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC100339

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel